| Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies M Lukas, B Velten, L Sellner, K Tomska, J Hüellein, T Walther, L Wagner, ... Leukemia 34 (11), 2934-2950, 2020 | 20 | 2020 |
| Methylglyoxal drives a distinct, nonclassical macrophage activation status FF Tsokanos, C Muley, S Khani, D Hass, T Fleming, G Wolff, A Bartelt, ... Thrombosis and Haemostasis 121 (11), 1464-1475, 2021 | 5 | 2021 |
| Role of ubiquilins for brown adipocyte proteostasis and thermogenesis C Muley, S Kotschi, A Bartelt Frontiers in Endocrinology 12, 739021, 2021 | 5 | 2021 |
| Fuse your mitochondria, lose appetite: an anorexic, anti‐obesity sphingolipid C Muley, A Bartelt EMBO Molecular Medicine 13 (8), e14618, 2021 | 3 | 2021 |
| Time-dependent melatonin secretion is associated with mitochondrial function in peripheral blood mononuclear cells (PBMC) of male volunteers C Silaidos, J Grube, C Muley, GP Eckert Mitochondrion 53, 21-29, 2020 | 3 | 2020 |
| Loss of myeloid cannabinoid CB1 receptor confers atheroprotection by reducing macrophage proliferation and immunometabolic reprogramming Y Wang, G Li, B Chen, G Shakir, M Volz, EPC Vorst, SL Maas, C Muley, ... bioRxiv, 2023.04. 06.535832, 2023 | 1 | 2023 |
| Dicer prevents activation of the type I interferon pathway in lipid-loaded macrophages N Li, C Muley, I Forne, A Bartelt, A Imhof, W Enard, M Nazari-Jahantigh, ... European Heart Journal 43 (Supplement_2), ehac544. 3083, 2022 | | 2022 |
| Nfe2l1 protects white adipocytes from cholesterol-induced inflammation C Muley, J Caesar, A Bartelt Atherosclerosis 355, 42, 2022 | | 2022 |
| NFE2L1 protects adipocytes from cholesterol-induced inflammation C Muley, J Caesar, S Kotschi, A Bartelt Atherosclerosis 331, e145, 2021 | | 2021 |
| A landscape of drug combination effects in Chronic Lymphocytic Leukemia generated by ex vivo pharmacogenomics screening M Lukas, B Velten, L Sellner, K Tomska, J Huellein, T Walther, C Muley, ... ONCOLOGY RESEARCH AND TREATMENT 41, 31-31, 2018 | | 2018 |
| SYSTEMATIC DRUG SENSITIVITY SCREENING IN LYMPHOID MALIGNANCIES IDENTIFIES VULNERABILITIES OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH HIGH RISK ABERRATIONS L Sellner, M Oles, S Anders, M Zapatka, M Lukas, M Slabicki, C Blume, ... Haematologica 99, 316-317, 2014 | | 2014 |
| 827: Ex vivo combinatorial screen to identify drug sensitivity and rational treatment of chronic lymphocytic leukemia M Lukas, L Sellner, M Oles, J Huellein, S Anders, T Stolz, C Muley, ... European Journal of Cancer, S200, 2014 | | 2014 |
